Skip to main content
Premium Trial:

Request an Annual Quote

Axela Biosensors, Abnova to Co-Develop Reagents for Axela's DotLab Systems

NEW YORK (GenomeWeb News) – Axela Biosensors and Abnova of Taiwan today said they plan to co-develop reagents and biomarker panels to be used on Axela's dotLab system.
 
According to the companies, the dotLab system is a real-time protein-detection technology that can accelerate the analysis, validation, and commercialization of protein biomarkers.
 
Specifically, Abnova said it will optimize a series of monoclonal antibodies for the quantitation of specific serum protein biomarkers for use with Axela’s dotLab sensors.
 
Researchers will then be able to combine these monoclonal antibodies with their own reagents to create custom panels for multiplexed biomarker detection.
 
Financial terms of the deal were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more